Aptamers

2023 Activity indicators

1 European competitive project led: EU-LAC
6 competitive public projects: ISCIII, MINECO, MICINN
1 competitive HR contract
12 publications
IF: 79.92
Q1 publications: 6 (50%)
D1 publications: 1 (8.3%)
3 thesis
Evaluators of projects in national institutions: 3 PI
Members of editorial committees: 1 PI
7 active patent families with priority patent:
- P201430955 'TLR4-specific aptamers and their potential use for stroke treatment'. Entry into national phases in 15 countries
- P201930524 'FPR2 receptor agonist aptamers' with PCT/ES2020/070378 and national phase entry in the US and Europe.
- EP 18 382 888.8 'Aptamers specific against human MNK1 protein and their use in MNK1 detection method and as MNK1 inhibitor' with PCT/EP2019/083547 and national phase entry in Europe and the US
- EP17382610 'MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells' with PCTEP2018/06815 extended in USA and Europe.
- EP21382710.8 'Aptamers against the hepatitis C virus core protein' with PCT/EP2022/071188
- EP22382616.5 'DNA aptamer conjugates recognizing and degrading coronavirus proteins'.
- EP22382617.3 'DNA aptamer conjugates recognizing and degrading coronavirus proteins'.
3 actions with impact on society: podcast, science and innovation week, talks
5 visitors and 12.4 months stay:
- Aptus Biotech S.L.
- Complutense University of Madrid
- University of Alcalá
- Benjamín Rúa Secondary School

Award of the first competitive European project of the 'ABSarbo' group, financed in the EU-LAC European call for proposals, which seeks new biotechnological tools through aptamers against arboviruses.
Award of a research project in the call of the National Plan (ISCIII), led by Dr. Mª Elena Martín, entitled 'Study of the mechanism of action of the APMNKQ2 aptamer against MNK1 as an antitumour drug (PID2022/142086OB-100)'.
Defence of 3 new doctoral theses by members of the research group describing the therapeutic use in cancer of aptamers developed in our laboratory.
Publication of the results of the phase IIa clinical study of the APTOLL aptamer, developed by the IRYCIS aptamer group in collaboration with Aptus Biotech (Hernandez-Jimenez et al., 2023. Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment A Phase 1/2 Randomized Clinical Trial. JAMA Neurology. AMER MEDICAL ASSOC. 80-8, pp.779-788. https://doi.org/10.1001/jamaneurol.2023.1660)
Participation of UCA-Aptamers, constituted from the research group and which provides an aptamer selection service to third parties, in different project applications from research groups and companies.